|1.||Bossie, Cynthia A: 16 articles (01/2014 - 07/2008)|
|2.||Canuso, Carla M: 14 articles (03/2015 - 07/2008)|
|3.||Alphs, Larry: 13 articles (04/2015 - 12/2009)|
|4.||Turkoz, Ibrahim: 12 articles (03/2015 - 07/2008)|
|5.||Hough, David: 11 articles (09/2015 - 05/2008)|
|6.||Lim, Pilar: 11 articles (05/2012 - 02/2007)|
|7.||Gopal, Srihari: 9 articles (09/2015 - 01/2013)|
|8.||Fu, Dong-Jing: 9 articles (04/2015 - 01/2011)|
|9.||Kramer, Michelle: 9 articles (01/2011 - 02/2007)|
|10.||Nuamah, Isaac: 8 articles (09/2015 - 12/2011)|
|1.||Schizophrenia (Dementia Praecox)
06/01/2010 - "Paliperidone ER is an effective and well-tolerated oral atypical antipsychotic that provides an important new treatment option for patients with schizophrenia. "
08/01/2015 - "The present study demonstrates that flexible dose of paliperidone resulted in a significant improvement in functioning and reduction in symptoms in patients with recent onset schizophrenia."
07/09/2010 - "Paliperidone ER 3-12 mg/day improved Positive and Negative Syndrome Scale (PANSS) total scores (primary endpoint) from baseline to study end to a significantly greater extent than placebo in 6-week, double-blind trials in patients with acute symptoms of schizophrenia. "
07/01/2007 - "In this study, all doses of paliperidone ER were effective in significantly improving the symptoms of schizophrenia and personal and social functioning and were generally well tolerated. "
12/15/2011 - "With weight-based treatment, only paliperidone ER Medium-treatment (3-6 mg) resulted in significant improvement in symptoms of schizophrenia in adolescents, as did 3, 6, and 12 mg by actual dose strengths. "
|2.||Psychotic Disorders (Schizoaffective Disorder)
06/01/2011 - "The clinical efficacy of paliperidone was demonstrated in two 6-week, randomized, double-blind, placebo-controlled, multicentre trials in patients with schizoaffective disorder. "
12/01/2015 - "To review the efficacy and tolerability of paliperidone for schizoaffective disorder, we conducted a systematic literature search of studies of paliperidone in the treatment of schizoaffective disorder, and briefly reviewed evidence regarding the somewhat controversial nature of that diagnostic entity. "
08/15/2013 - "This post hoc analysis used the database (N=614) from two 6-week, randomized, placebo-controlled studies of paliperidone ER versus placebo in symptomatic subjects with schizoaffective disorder assessed using HAM-D-17, YMRS, and CGI-S-SCA scales. "
08/01/2012 - "Two randomized, placebo-controlled, short-term studies have documented the efficacy and tolerability of paliperidone ER in the treatment of schizoaffective disorder, but no long-term or maintenance study has been conducted in patients with schizoaffective disorder. "
05/01/2010 - "This study was designed to assess efficacy and safety of paliperidone extended-release (ER) in patients with schizoaffective disorder. "
|3.||Bipolar Disorder (Mania)
10/01/2010 - "Subjects with prominent manic or depressive symptoms showed greater improvement with paliperidone ER versus placebo: mean (SE) Young Mania Rating Scale (-10.6 [0.9] vs -5.7 [1.2], respectively) and 21-item Hamilton Rating Scale for Depression (-10.2 [0.7] vs -6.2 [1.1], respectively). "
06/01/2013 - "This study evaluates the safety and efficacy of paliperidone monotherapy as an acute treatment of mania and related symptoms in youth with bipolar spectrum disorders. "
08/01/2012 - "Two 3-week, randomized, double-blind, placebo-controlled studies showed that paliperidone ER is significantly superior to placebo for treating patients with bipolar disorder, but the results were driven by certain subpopulations. "
05/01/2012 - "Paliperidone ER monotherapy was efficacious in treating acute mania in two 3-week studies in patients with bipolar I disorder. "
01/01/2012 - "A literature search was performed from January 1966 through January 2012 using PreMEDLINE, MEDLINE, EMBASE, IPA, and ClinicalTrials.gov to identify articles in English regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or mixed episodes or in the maintenance treatment of BD I. There are currently three published studies relating to the use of paliperidone ER for the treatment of BD. "
|4.||Autistic Disorder (Autism)
09/01/2012 - "This is a prospective, 8-week open-label study of paliperidone in 25 adolescents and young adults with autism. "
09/01/2012 - "The aim of this study is to determine the effectiveness and tolerability of paliperidone for irritability in autism. "
09/01/2012 - "Paliperidone for irritability in adolescents and young adults with autistic disorder."
02/01/2010 - "Paliperidone for irritability in autistic disorder."
01/01/2004 - "The aim of the present study was to evaluate the effectiveness and tolerability of risperidone in children with autistic disorder and to examine the correlation between plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) and the clinical response. "
|5.||Sleep Initiation and Maintenance Disorders (Insomnia)
08/01/2015 - "Paliperidone ER was generally well tolerated, with frequently reported treatment-emergent adverse events being insomnia, anxiety and somnolence. "
09/01/2007 - "Paliperidone extended-release was well tolerated and improved sleep architecture and sleep continuity in patients diagnosed with schizophrenia and concomitant insomnia."
02/01/2008 - "Headache and insomnia were the most common adverse events in patients treated with paliperidone ER in the 6-week trials (pooled data: 11%-18% and 4%-14%, respectively). "
09/01/2007 - "The effects of paliperidone extended-release on sleep architecture in patients with schizophrenia-related insomnia were evaluated in this multicenter, double-blind, randomized, placebo-controlled study. "
07/01/2008 - "AEs > or =10% with paliperidone ER versus placebo were headache (16.2 vs. 16.1%), insomnia (14.1 vs. 16.1%), and agitation (8.5 vs. 10.7%). "
|1.||Risperidone (Risperdal Consta)
|6.||Antipsychotic Agents (Antipsychotics)